"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
This drug is contraindicated in individuals who have shown hypersensitivity to any of its components.
This drug, because of the sulfonamide component, should not be used in patients with a history of sulfonamide sensitivities, and in pregnant females at term.
Last reviewed on RxList: 8/24/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Urobiotic Information
Report Problems to the Food and Drug Administration
Find out what women really need.